Results 41 to 50 of about 1,577 (196)

The present and future of immunocytokines for cancer treatment

Cellular and Molecular Life Sciences, 2022
AbstractMonoclonal antibody (mAb) therapy has successfully been introduced as treatment of several lymphomas and leukemias. However, solid tumors reduce the efficacy of mAb therapy because of an immune-suppressive tumor micro-environment (TME), which hampers activation of effector immune cells.
Dennis Y. Gout, Lotte S. Groen, Marjolein van Egmond   +2 more
openaire   +2 more sources

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

Journal for ImmunoTherapy of Cancer, 2019
Background Unlike some adult cancers, most pediatric cancers are considered immunologically cold and generally less responsive to immunotherapy. While immunotherapy has already been incorporated into standard of care treatment for pediatric patients with
Julie Voeller, Amy K. Erbe, Jacob Slowinski, Kayla Rasmussen, Peter M. Carlson, Anna Hoefges, Sabrina VandenHeuvel, Ashley Stuckwisch, Xing Wang, Stephen D. Gillies, Ravi B. Patel, Alvin Farrel, Jo Lynne Rokita, John Maris, Jacquelyn A. Hank, Zachary S. Morris, Alexander L. Rakhmilevich, Paul M. Sondel   +17 more
doaj   +1 more source

DataSheet_1_Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy.pdf

, 2022
Tumor-targeting antibody (Ab)-fused cytokines, referred to as immunocytokines, are designed to increase antitumor efficacy and reduce toxicity through the tumor-directed delivery of cytokines.
Jung-Eun Kim (83763), Wook Kim (220700), Yong-Sung Kim (111377), Keunok Jung (9960644), Sojung Yoo (12449395)   +4 more
core   +1 more source

Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo

OncoImmunology, 2017
NHS-IL12 is an immunocytokine, a fusion protein of IL12's functional domains and a necrosis-targeting antibody, which has shown significant effects against human rhabdomyosarcoma xenografts in a humanized tumor model, including terminal growth arrest and
Franziska Eckert, Ivan Jelas, Moritz Oehme, Stephan M. Huber, Katja Sonntag, Christian Welker, Stephen D. Gillies, Wolfgang Strittmatter, Daniel Zips, Rupert Handgretinger, Karin Schilbach   +10 more
doaj   +1 more source

Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression

mAbs, 2021
LIGHT is a member of the tumor necrosis factor superfamily, which has been claimed to mediate anti-tumor activity on the basis of cancer cures observed in immunocompetent mice bearing transgenic LIGHT-expressing tumors.
Marco Stringhini, Jacqueline Mock, Vanessa Fontana, Patrizia Murer, Dario Neri   +4 more
doaj   +1 more source

PD-1-Cis IL-2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1-IL2v). [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Binding in cis‐configuration to the PD‐1 receptor (PD‐1) and IL‐2βγ receptor (IL‐2Rβγ) has been shown to lead to differentiation of CD8 T cells to better effectors, which is anticipated to drive efficacy of the immune‐targeted cytokine eciskafusp alfa, or PD1‐IL2v.
Hutchinson LG, Lewin TD, Lauener L, Martin-Facklam M, Muecke M, Teichgraeber V, Codarri Deak L.   +6 more
europepmc   +2 more sources

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy

Antibodies, 2012
Immunocytokines (ICs) are a class of molecules created by linking tumor-reactive monoclonal antibodies to cytokines that are able to activate immune cells.
Paul M. Sondel, Stephen D. Gillies
doaj   +1 more source

Immunocytokines turn up the heat in glioblastoma

Nature Reviews Drug Discovery, 2020
2558 Background: There is an urgent need for novel treatment options for patients with glioblastoma, the most frequent malignant primary brain tumor. In contrast to other types of cancer, immunotherapeutic approaches have so far not been successful against glioblastoma. Converting the glioma microenvironment from a "cold" and immunosuppressive status
Roth, Patrick, Weiss, Tobias, Puca, Emanuele, Silginer, Manuela, Hemmerle, Teresa, Pazahr, Shila, Bink, Andrea, Neri, Dario, Weller, Michael   +8 more
  +10 more sources

A Phase 1b Study of Humanized Ks-Interleukin-2 (Huks-Il2) Immunocytokine with Cyclophosphamide in Patients with Epcam-Positive Advanced Solid Tumors [PDF]

, 2013
BackgroundHumanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent.MethodsPhase 1b study in patients with ...
Connor, Joseph P, Lewis, Lionel D, Cristea, Mihaela C, Lewis, Nancy L   +3 more
core   +1 more source

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Nature Communications, 2021
The immunocytokine NHS-IL12 is targeted to necrotic tumour areas to prompt an immune response. Authors show here in mouse colon and breast models that the combination of histone deacetylase inhibitor, Entinostat, and NHS-IL12 generates a tumour ...
Kristin C. Hicks, Paul L. Chariou, Yohei Ozawa, Christine M. Minnar, Karin M. Knudson, Thomas J. Meyer, Jing Bian, Margaret Cam, Jeffrey Schlom, Sofia R. Gameiro   +9 more
doaj   +1 more source